{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T10:55:58Z","timestamp":1774954558301,"version":"3.50.1"},"reference-count":23,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OVS"],"published-print":{"date-parts":[[2012,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose.<\/jats:title>\n                    <jats:p>Imatinib mesylate (Gleevec) is a chemotherapy medication developed to treat chronic myelogenous leukemia as well as gastrointestinal stromal tumors (Savage, N Engl J Med 2002;346:683\u201393). Ocular side effects are commonly reported with the use of imatinib mesylate, such as periorbital edema and epiphora. More serious ocular side effects, such as optic disc edema, are rarely reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Report.<\/jats:title>\n                    <jats:p>This case is of a patient who presented with monocular painless loss of vision in the left eye from a previously documented 20\/20 to 20\/70 shortly after starting treatment with imatinib mesylate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>Every aspect of the ocular presentation and clinical history were addressed to unveil the cause of the disc edema. After ruling out all other causes, the patient was later diagnosed with unilateral optic disc edema as a related side effect of the toxicity from imatinib mesylate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>The properties of imatinib mesylate and the possible etiology of secondary optic disc edema are discussed. This study aims to highlight the importance of systemic medications review for possible etiology of ocular disease as well as the multidisciplinary approach to managing oncology patients with ocular side effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/opx.0b013e318269111d","type":"journal-article","created":{"date-parts":[[2012,9,7]],"date-time":"2012-09-07T03:35:35Z","timestamp":1346988935000},"source":"Crossref","is-referenced-by-count":24,"title":["Imatinib Mesylate (Gleevec) Induced Unilateral Optic Disc Edema"],"prefix":"10.1002","volume":"89","author":[{"given":"Crystal","family":"DeLuca","sequence":"first","affiliation":[{"name":"VA Nebraska\u2010Western Iowa Healthcare System Lincoln Nebraska"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Shenouda\u2010Awad","sequence":"additional","affiliation":[{"name":"VA Connecticut Healthcare System West Haven Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Haskes","sequence":"additional","affiliation":[{"name":"VA Connecticut Healthcare System West Haven Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Wrzesinski","sequence":"additional","affiliation":[{"name":"VA Connecticut Healthcare System West Haven Connecticut"},{"name":"Oncology Department Yale University Medical School New Haven Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,10,1]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"crossref","first-page":"134","DOI":"10.5858\/2008-0083-RSR2.1","article-title":"Gastrointestinal stromal tumors: a review of the literature","volume":"134","author":"Laurini JA","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"e_1_2_7_3_1","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/bjs.4046","article-title":"Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours","volume":"90","author":"Langer C","year":"2003","journal-title":"Br J Surg"},{"key":"e_1_2_7_4_1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s10434-001-0050-4","article-title":"Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database","volume":"8","author":"Crosby JA","year":"2001","journal-title":"Ann Surg Oncol"},{"key":"e_1_2_7_5_1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/1471-2407-10-199","article-title":"A long\u2010term follow\u2010up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome","volume":"10","author":"Zhu J","year":"2010","journal-title":"BMC Cancer"},{"key":"e_1_2_7_6_1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1634\/theoncologist.2008-0255","article-title":"Approval summary: imatinib mesylate in the treatment of metastatic and\/or unresectable malignant gastrointestinal stromal tumors","volume":"14","author":"Cohen MH","year":"2009","journal-title":"Oncologist"},{"key":"e_1_2_7_7_1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10792-007-9038-9","article-title":"Imatinib\u2010induced optic neuritis in a patient of chronic myeloid leukemia","volume":"27","author":"Govind Babu K","year":"2007","journal-title":"Int Ophthalmol"},{"key":"e_1_2_7_8_1","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1089\/108076803322279426","article-title":"Ocular side\u2010effects associated with imatinib mesylate (Gleevec)","volume":"19","author":"Fraunfelder FW","year":"2003","journal-title":"J Ocul Pharmacol Ther"},{"key":"e_1_2_7_9_1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.hoc.2008.11.003","article-title":"Ocular side effects associated with imatinib mesylate and perifosine for gastrointestinal stromal tumor","volume":"23","author":"Dogan SS","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"e_1_2_7_10_1","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.leukres.2007.10.016","article-title":"Ocular side effects in chronic myeloid leukemia patients treated with imatinib","volume":"32","author":"Breccia M","year":"2008","journal-title":"Leuk Res"},{"key":"e_1_2_7_11_1","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/sj.leu.2403364","article-title":"Visual disturbance due to retinal edema as a complication of imatinib","volume":"18","author":"Kusumi E","year":"2004","journal-title":"Leukemia"},{"key":"e_1_2_7_12_1","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10384-008-0561-7","article-title":"Optic disc edema as a possible complication of imatinib mesylate (Gleevec)","volume":"52","author":"Kwon SI","year":"2008","journal-title":"Jpn J Ophthalmol"},{"key":"e_1_2_7_13_1","volume-title":"Clinical Ophthalmology: A Systematic Approach","author":"Kanski JJ","year":"2007"},{"key":"e_1_2_7_14_1","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/B978-0-323-04332-8.00163-3","volume-title":"Ophthalmology","author":"Sadun A","year":"2009"},{"key":"e_1_2_7_15_1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra013339","article-title":"Imatinib mesylate\u2014a new oral targeted therapy","volume":"346","author":"Savage DG","year":"2002","journal-title":"N Engl J Med"},{"key":"e_1_2_7_16_1","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri GD","year":"2002","journal-title":"N Engl J Med"},{"key":"e_1_2_7_17_1","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","article-title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033","volume":"26","author":"Blanke CD","year":"2008","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_18_1","doi-asserted-by":"crossref","first-page":"79S","DOI":"10.1177\/1066896910369928","article-title":"Gastrointestinal stromal tumor and its mimics","volume":"18","author":"Rosai J","year":"2010","journal-title":"Int J Surg Pathol"},{"key":"e_1_2_7_19_1","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1126\/science.277.5323.242","article-title":"Pericyte loss and microaneurysm formation in PDGF\u2010B\u2010deficient mice","volume":"277","author":"Lindahl P","year":"1997","journal-title":"Science"},{"key":"e_1_2_7_20_1","first-page":"3649","article-title":"Platelet\u2010derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases","volume":"35","author":"Robbins SG","year":"1994","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_7_21_1","first-page":"1599","article-title":"Imatinib induces apoptosis by inhibiting PDGF\u2010 but not insulin\u2010induced PI 3\u2010kinase\/Akt survival signaling in RGC\u20105 retinal ganglion cells","volume":"15","author":"Biswas SK","year":"2009","journal-title":"Mol Vis"},{"key":"e_1_2_7_22_1","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.jcrs.2005.10.029","article-title":"Imatinib as a cause of cystoid macular edema following uneventful phacoemulsification surgery","volume":"31","author":"Masood I","year":"2005","journal-title":"J Cataract Refract Surg"},{"key":"e_1_2_7_23_1","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1634\/theoncologist.2009-0120","article-title":"Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors","volume":"15","author":"Cohen MH","year":"2010","journal-title":"Oncologist"},{"key":"e_1_2_7_24_1","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/BF02983993","article-title":"Conjunctival hemorrhagic events associated with imatinib mesylate","volume":"86","author":"Radaelli F","year":"2007","journal-title":"Int J Hematol"}],"container-title":["Optometry and Vision Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1097\/OPX.0b013e318269111d","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1097\/OPX.0b013e318269111d","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1097\/OPX.0b013e318269111d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:59:32Z","timestamp":1774951172000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1097\/OPX.0b013e318269111d"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["10.1097\/OPX.0b013e318269111d"],"URL":"https:\/\/doi.org\/10.1097\/opx.0b013e318269111d","archive":["Portico"],"relation":{},"ISSN":["1040-5488","1538-9235"],"issn-type":[{"value":"1040-5488","type":"print"},{"value":"1538-9235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}